Effector Therapeutics Inc (EFTR) — Cash Flow Reinvestment Rate

Latest as of June 2020: 0.00x

Effector Therapeutics Inc (EFTR) has a Cash Flow Reinvestment Rate of 0.00x as of June 2020, reinvesting $0.00 (capex $0.00 ) from operating cash flow of $11.98 Million. See EFTR cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.00x
(Capex + Investments) / Operating CF

Total Reinvested

$0.00
Capex + Investments

Operating Cash Flow

$11.98 Million
USD

Capital Expenditures

$0.00
USD

Effector Therapeutics Inc Cash Flow Reinvestment Rate (2020–2020)

Historical reinvestment intensity for Effector Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see Effector Therapeutics Inc (EFTR) cash flow conversion.

Annual Cash Flow Reinvestment Rate for Effector Therapeutics Inc (2020–2020)

Year-by-year capital reinvestment analysis for Effector Therapeutics Inc. See EFTR financial flexibility score to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2020 0.02x $308.00K $13.84 Million $154.00K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow